期刊文献+

自体腹水回输在卵巢过度刺激综合征治疗中的应用 被引量:2

Application of Autologous Ascites Reinfusion in Ovarian Hyperstimulation Syndrome
下载PDF
导出
摘要 自体腹水回输是在无菌密闭系统中将自身腹水引出体外,通过一定装置将其中水、电解质、尿素氮等中小分子物质滤出,而蛋白质等大分子被保留浓缩,回输至人体内的过程。其作为自身白蛋白重利用的一种方式,已较多应用于治疗肝硬化顽固性腹水和癌性腹水患者。卵巢过度刺激综合征(OHSS)主要发生在行促排卵治疗时,以双侧卵巢增大、高雌激素血症、腹水、电解质失衡和少尿为特征,严重者可以出现肝肾功能衰竭、血管栓塞甚至死亡。腹水是中重度患者的常见症状,由于OHSS腹水中不仅含蛋白质、代谢废物,还含有多种激素及炎性因子,直接回输可能会加重病情,因此自体腹水回输目前在OHSS治疗中应用极少。现就自体腹水回输技术在OHSS治疗中的应用作一综述。 The reinfusion of autologous ascites is the operational process under very sterile as draining ascites from body, filtering out water, electrolyte, urea nitrogen, and so on, concentrating proteins and other macromolecular substances, and then infusing back into body. It has been widely used for treating intractable ascites of cirrhosis and malignant ascites as a way of albumin reuse. Ovarian hyperstimulation syndrome (OHSS), a symptom occurring mainly in ovulation induction, is characterized by the bilateral ovarian enlargement, high vascular estrogen, ascites, electrolyte imbalance and oliguria. Serious OHSS may be accompanied by hepatic or/and renal failure, thromboembolism, or even death. Ascites is a common symptom of moderate or severe OHSS. Besides proteins and metabolic wastes, there are hormones and inflammatory factors in OHSS ascites, which means that infusing directly OHSS ascites may induce the conditional aggravation. The autologous reinfusion of OHSS ascites is rarely used at present. The application of autologous reinfusion of OHSS ascites was reviewed in this paper.
作者 裴雪婷 周平
出处 《国际生殖健康/计划生育杂志》 CAS 2015年第1期80-82,共3页 Journal of International Reproductive Health/Family Planning
关键词 腹水 腹水液 卵巢过度刺激综合征 治疗 Ascites Ascitic fluid Ovarian hyperstimulation syndrome Therapy
  • 相关文献

参考文献18

  • 1Hanevik HI’Hilmarsen HT,Skjelbred CF,et al. Increased risk ofovarian hyperstimulation syndrome following controlled ovarianhyperstimulation in patients with vascular endothelial growth factor+405 cc genotype[J]. Gynecol Endocrinol,2012,28(11):845-849.
  • 2Alama P,Bellver J,Vidal C,et al. GnRH analogues in theprevention of ovarian hyperstimulation syndrome [J]. Int JEndocrinol Metab,2013 ,11(2) : 107-116.
  • 3Mikolajclk A,Smol6r M,Biringer K,et al. Ovarial hyperstimulationsyndrome in the differential diagnostics of acute abdomen[J]. RozhlChir,2010,89(7):402-405.
  • 4金丽娜,缪立英,何小舟,刘金凤,李秀荣,薛丽娜.两种血液净化方法对维持性血液透析患者血清FGF-23的影响[J].齐齐哈尔医学院学报,2012,33(24):3327-3329. 被引量:9
  • 5Japanese CART Study Group,Matsusaki K, Ohta K,et al. Novelcell-free and concentrated ascites reinfusion therapy (KM-CART)for refractory ascites associated with cancerous peritonitis: its effectand future perspectives [J]. Int J Clin Oncol,2011,16 (4) :395-400.
  • 6Orimi S,Mizuno K,Narahara M,et al. A study of appropriate flowrate settings for cell -free and concentrated ascites reinfusiontherapy and change of cytokine concentrations in ascites [J]. TherApher Dial,2011,15(4):411-414.
  • 7Ronco C,Kim JC,Garzotto F,et al. Hydrodynamic analysis of theminiaturized hemofilter for a wearable ultrafiltration device [J].Blood Purif,2013,35( 1/2/3): 127-132.
  • 8Mineshima M, Eguchi K. Development of intermittent infusionhemodiafiltration using ultrapure dialysis fluid with an automateddialysis machine[J]. Blood Purif, 2013,35(Suppl 1) :55-58.
  • 9Ito M, Harada T, Iwabe T,et al. Cytokine levels in a patient withsevere ovarian hyperstimulation syndrome before and after theultrafiltration and reinfusion of ascitic fluid [J]. J Assist ReprodGenet,2000,17(2):118-120.
  • 10Takamizawa S, Shibahara H,Taneichi A,et al. Dynamic changes ofthe immunoglobulins in patients with severe ovarianhyperstimulation syndrome: efficacy of a novel treatment usingperitoneo-venous shunt [J]. Am J Reprod Immunol, 2002,47 (1):25-30.

二级参考文献9

  • 1Gutiérrez OM,Mannstadt M,Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis[J].New England Journal of Medicine,2008,(06):584-592.
  • 2Nakanishi S,Kazama J J,Nii-Kono T. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients[J].Kidney International,2005,(03):1171-1178.
  • 3Miyamoto K,Ito M,Tatsumi S. New aspect of renal phosphate reabsorption:the type Ⅱc sodium-dependent phosphate transporter[J].American Journal of Nephrology,2007,(05):503-515.
  • 4Goetz R,Nakada Y,Hu MC. Isolated C-terminal tail of FGF23 alleviates hypophosph-atemia by inhibiting FGF23-FGFR-Klotho complex formation[J].Proceedings of the National Academy of Sciences(USA),2010,(01):407-412.
  • 5Razzaque MS,Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis[J].Journal of Endocrinology,2007,(01):1-10.
  • 6Perwad F,Zhang MY,Tenenhouse HS. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro[J].American Journal of Physiology-Renal Physiology,2007,(05):F1577-F1583.
  • 7Tentori F,Blayney MJ,Albert JM. Mortality risk for dialysis patients with different levels of serum calcium,phosphorus,and PTH:the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].American Journal of Kidney Diseases,2008,(03):519-530.doi:10.1053/j.ajkd.2008.03.020.
  • 8Torres PU,Friedlander G,De Vernejoul MC. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients[J].Kidney International,2008,(01):102-107.
  • 9Patrier L,Dupuy AM,Granger Vallée A. FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis[J].Journal of Nephrology,2012.27-30.

共引文献9

同被引文献19

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部